156 related articles for article (PubMed ID: 31348323)
1. Comparison of efficacy and safety of S-1 and capecitabine in patients with metastatic colorectal carcinoma: A systematic review and meta-analysis.
Chen J; Wang J; Xu T
Medicine (Baltimore); 2019 Jul; 98(30):e16667. PubMed ID: 31348323
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety assessment of S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma: A system review and meta-analysis.
Chen J; Wang J
Medicine (Baltimore); 2019 Jun; 98(23):e15999. PubMed ID: 31169742
[TBL] [Abstract][Full Text] [Related]
3. Comparison of S-1-based vs. capecitabine-based adjuvant chemotherapy for patients with gastric cancer: a systematic review and meta-analysis.
Zhang Q; Qian Y; Yin Y
Eur J Clin Pharmacol; 2021 Dec; 77(12):1791-1804. PubMed ID: 34275019
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of capecitabine-based versus S-1-based chemotherapy for metastatic or recurrent gastric cancer: a systematic review and meta-analysis of clinical randomized trials.
Feng Z; Yan P; Hou X; Feng J; He X; Yang K
Ann Palliat Med; 2020 May; 9(3):883-894. PubMed ID: 32389017
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysis.
Zhang X; Cao C; Zhang Q; Chen Y; Gu D; Shen Y; Gong Y; Chen J; Tang C
PLoS One; 2014; 9(1):e84230. PubMed ID: 24392116
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
Hamaguchi T; Shimada Y; Mizusawa J; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Takiguchi N; Yatsuoka T; Takii Y; Ojima H; Masuko H; Kubo Y; Mishima H; Yamaguchi T; Bando H; Sato T; Kato T; Nakamura K; Fukuda H; Moriya Y
Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):47-56. PubMed ID: 29079411
[TBL] [Abstract][Full Text] [Related]
7. Oral versus intravenous fluoropyrimidines for colorectal cancer.
Chionh F; Lau D; Yeung Y; Price T; Tebbutt N
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD008398. PubMed ID: 28752564
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group.
Kwakman JJM; Simkens LHJ; van Rooijen JM; van de Wouw AJ; Ten Tije AJ; Creemers GJM; Hendriks MP; Los M; van Alphen RJ; Polée MB; Muller EW; van der Velden AMT; van Voorthuizen T; Koopman M; Mol L; van Werkhoven E; Punt CJA
Ann Oncol; 2017 Jun; 28(6):1288-1293. PubMed ID: 28383633
[TBL] [Abstract][Full Text] [Related]
9. Updated Survival Analysis of the Randomized Phase III Trial of S-1 Versus Capecitabine in the First-Line Treatment of Metastatic Colorectal Cancer by the Dutch Colorectal Cancer Group.
Kwakman JJM; van Werkhoven E; Simkens LHJ; van Rooijen JM; van de Wouw YAJ; Tije AJT; Creemers GM; Hendriks MP; Los M; van Alphen RJ; Polée MB; Muller EW; van der Velden AMT; van Voorthuizen T; Koopman M; Mol L; Punt CJA
Clin Colorectal Cancer; 2019 Jun; 18(2):e229-e230. PubMed ID: 30782413
[No Abstract] [Full Text] [Related]
10. S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis.
He MM; Wu WJ; Wang F; Wang ZQ; Zhang DS; Luo HY; Qiu MZ; Wang FH; Ren C; Zeng ZL; Xu RH
PLoS One; 2013; 8(12):e82798. PubMed ID: 24349363
[TBL] [Abstract][Full Text] [Related]
11. [A multicenter clinical study for the comparison of S-1 versus capecitabine in the treatment of advanced breast cancer].
Li Y; Jiang D; Wu YY; Li LL; Cui YZ; Dong Q
Zhonghua Zhong Liu Za Zhi; 2017 Aug; 39(8):607-612. PubMed ID: 28835084
[No Abstract] [Full Text] [Related]
12. Efficacy of S-1 vs capecitabine for the treatment of gastric cancer: a meta-analysis.
He AB; Peng XL; Song J; Zhang JX; Dong WG; Luo RF; Tang Y
World J Gastroenterol; 2015 Apr; 21(14):4358-64. PubMed ID: 25892887
[TBL] [Abstract][Full Text] [Related]
13. Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review.
Winther SB; Zubcevic K; Qvortrup C; Vestermark LW; Jensen HA; Krogh M; Sorbye H; Pfeiffer P;
Acta Oncol; 2016 Jul; 55(7):881-5. PubMed ID: 27181284
[TBL] [Abstract][Full Text] [Related]
14. A Meta-analysis Reveals S-1-based Chemotherapy Improves the Survival of Patients With Advanced Gastric Cancer.
Wu FL; Lu DC; Ying YP; Huang JJ; Zhou AM; Jiang DK; Chen MW; Yang X; Zhou J; Huang HQ; Zeng HY
Medicine (Baltimore); 2015 Apr; 94(16):e652. PubMed ID: 25906091
[TBL] [Abstract][Full Text] [Related]
15. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Hong YS; Park YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Jo SJ; Lee JW
Lancet Oncol; 2012 Nov; 13(11):1125-32. PubMed ID: 23062232
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer.
Yamada Y; Yamaguchi T; Matsumoto H; Ichikawa Y; Goto A; Kato K; Hamaguchi T; Shimada Y
Invest New Drugs; 2012 Aug; 30(4):1690-6. PubMed ID: 21894500
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study.
Li J; You J; Si W; Zhu Y; Chen Y; Yang B; Han C; Linghu R; Zhang X; Jiao S; Yang J
Medicine (Baltimore); 2015 Oct; 94(41):e1340. PubMed ID: 26469889
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Platinum/S-1 and Platinum/5-Fluorouracil as First-Line Chemotherapy for Advanced Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis Based on Randomized Controlled Trials.
Luo D; Wang L; Chen X; Xiong Y; Yi F; Ding J; Ding H; Wei Y; Zhang W
Chemotherapy; 2020; 65(1-2):11-20. PubMed ID: 32535588
[TBL] [Abstract][Full Text] [Related]
19. Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study).
Kinos S; Hagman H; Halonen P; Soveri LM; O'Reilly M; Pfeiffer P; Frödin JE; Sorbye H; Heervä E; Liposits G; Kallio R; Ålgars A; Ristamäki R; Salminen T; Bärlund M; Shah CH; McDermott R; Röckert R; Flygare P; Kwakman J; Teske A; Punt C; Glimelius B; Österlund P
Acta Oncol; 2024 May; 63():248-258. PubMed ID: 38698698
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
